MK-677 Ibutamoren Peptide Research – Complete Guide

Table of Contents

• MK-677 Quick Facts and Research Snapshot
• What is MK-677 Ibutamoren?
• MK-677 Molecular Structure and Core Properties
• MK-677 Mechanisms of Action Being Investigated
• MK-677 Major Areas of Research
• MK-677 Pharmacokinetics and Biological Distribution
• MK-677 Research Limitations and Evidence Gaps
• MK-677 Regulatory and Research Status
• MK-677 Key Research Findings
• Frequently Asked Questions
• References

MK-677 Quick Facts and Research Snapshot

• Primary Research Areas: Body composition, bone turnover, nitrogen balance, GH deficiency, Alzheimer’s disease
• Classification: Non-peptide ghrelin receptor agonist; orally active growth hormone secretagogue
• Molecular Target: Growth hormone secretagogue receptor subtype 1a (GHS-R1a), the same receptor activated by the hunger hormone ghrelin
• Administration Route: Oral (capsules), the primary differentiator from injectable growth hormone releasing peptides
• Research Status: Investigational compound; multiple completed human clinical trials; no FDA-approved indication
• Key Mechanisms: GHS-R1a receptor activation, pulsatile GH stimulation, IGF-1 (insulin-like growth factor-1) elevation, fat-free mass modulation
• Published Human Trials: Multiple completed studies (1997-2008); one large Alzheimer’s trial (563 participants)
• Clinical Trial Status: Several completed; at least one halted early due to congestive heart failure signal
• Regulatory Classification: Unapproved investigational compound (FDA); prohibited in sport (WADA 2024 Prohibited List, Category S2)
• WADA Status: Prohibited at all times (in-competition and out-of-competition)

What is MK-677 Ibutamoren?

MK-677, known generically as ibutamoren and also identified in research literature as MK-0677 and L-163,191, is a non-peptide small molecule developed to stimulate growth hormone secretion through oral administration. Its development addressed a practical limitation in growth hormone research: prior growth hormone-releasing peptides required injection, while MK-677 achieves systemic absorption through the gastrointestinal tract. The compound functions as a ghrelin mimetic. Ghrelin is a naturally occurring peptide hormone produced primarily in the stomach. It triggers hunger, stimulates growth hormone release, and regulates energy balance. MK-677 binds to the same receptor that ghrelin activates: the growth hormone secretagogue receptor subtype 1a (GHS-R1a), located in the hypothalamus and pituitary gland. By binding this receptor, MK-677 triggers pulsatile growth hormone release from the anterior pituitary. The pituitary signal then prompts the liver to produce IGF-1 (insulin-like growth factor-1), which mediates many of growth hormone’s downstream effects. An important classification distinction: MK-677 is not a peptide. It is a non-peptide small molecule that mimics a peptide hormone’s action at the receptor level. This separates it from true peptide growth hormone secretagogues such as GHRP-2 and GHRP-6, which require injection and are structurally classified as peptides. MK-677’s oral bioavailability and distinct chemical class have made it a subject of unique research interest since the mid-1990s. Human clinical research on MK-677 spans multiple decades, study populations, and research questions. Trials have investigated its effects in healthy young men, elderly adults, growth hormone-deficient patients, obese subjects, and Alzheimer’s disease patients. The body of evidence covers growth hormone and IGF-1 elevations, body composition changes, bone turnover markers, nitrogen balance, and cognitive function. Results have been mixed: some findings show meaningful physiological effects, while others produced null results, including a large Alzheimer’s disease trial and functional outcome measurements in elderly subjects. MK-677 remains an unapproved investigational compound. It is classified for research use only and is prohibited in competitive sport by the World Anti-Doping Agency. Researchers exploring the broader landscape of growth hormone-related compounds will find additional context in the Cenexa Labs peptide research library, which covers related secretagogues and growth hormone axis modulators.

MK-677 Molecular Structure and Core Properties

Chemical Structure and Specifications

Property	Specification
Molecular Formula	C27H36N4O5S
Molecular Weight	528.66 g/mol (this relatively low molecular weight supports oral absorption and systemic distribution)
CAS Number	159752-10-0
Drug Class	Non-peptide ghrelin receptor agonist (growth hormone secretagogue)
Primary Target	GHS-R1a (growth hormone secretagogue receptor subtype 1a)
Solubility	Orally bioavailable; soluble in standard research solvents
Administration	Oral (capsules, liquid solution)
Also Known As	Ibutamoren mesylate, MK-0677, L-163,191

Key Structural Features

MK-677 is a sulfonamide compound, a chemical class defined by a sulfur atom bonded to two oxygen atoms and a nitrogen atom. This sulfonamide backbone gives MK-677 the molecular architecture needed to mimic ghrelin’s receptor-binding activity without requiring a peptide backbone. Peptide bonds are broken down by digestive enzymes before absorption can occur, so MK-677’s non-peptide structure is what directly enables oral administration. This is the core structural reason all published clinical trials used oral dosing rather than injection. The compound’s affinity for GHS-R1a is high and specific. Its binding profile activates the same intracellular signaling cascade that endogenous ghrelin initiates, producing downstream growth hormone secretion. This receptor selectivity is a central research interest because targeting GHS-R1a theoretically preserves the pulsatile, episodic pattern of GH release. That natural pulsatile pattern differs from the continuous GH elevation produced by injecting recombinant GH directly, making MK-677 a useful tool for studying the effects of stimulated versus administered GH. Stability under physiological conditions supports the oral route. MK-677 survives gastric acid exposure and intestinal enzymatic activity sufficiently to achieve systemic circulation. This enables the consistent oral dosing protocols used across all published clinical trials. For researchers sourcing reference-grade material, purity verification is essential. The Cenexa Pure Process describes the manufacturing and third-party testing standards relevant to research compound quality.

MK-677 Mechanisms of Action Being Investigated

MK-677 works by fitting into a specific receptor in the brain and pituitary gland, triggering a cascade of hormonal signals. Think of the GHS-R1a receptor as a lock. MK-677 is a key that fits that lock and turns on a growth hormone release signal. Multiple signaling steps have been characterized in animal studies, with some elements confirmed in human clinical data.

MK-677 GHS-R1a Receptor Activation and GH Secretion

MK-677 binds the GHS-R1a receptor in the hypothalamus and anterior pituitary. This binding triggers growth hormone release in pulses rather than continuously. Pulsatile release matches the body’s natural GH secretion pattern. Exogenous recombinant GH administered by injection creates a flat, non-pulsatile elevation. MK-677’s receptor-mediated mechanism preserves the natural episodic rhythm. In clinical studies, single oral doses produced peak GH concentrations of approximately 55.9 micrograms per liter. After one week of daily dosing, peak GH settled at approximately 22.6 micrograms per liter, suggesting partial adaptation [10]. Across dose escalation studies in growth hormone-deficient adults, 24-hour mean GH concentrations increased by 79-82% at doses between 10 and 50 mg per day [16].

MK-677 IGF-1 Axis Stimulation

Elevated GH signals the liver to produce two key molecules: IGF-1 (insulin-like growth factor-1) and IGFBP-3 (IGF binding protein-3, a carrier protein that regulates how much IGF-1 is available to tissues). IGF-1 mediates many of GH’s anabolic downstream effects, including nitrogen retention, fat-free mass preservation, and bone turnover stimulation. In human trials, MK-677 consistently raised IGF-1 concentrations across populations:

• 36-42% increase from a baseline of 186 ng/mL to 264 ng/mL in healthy men under caloric restriction [10]
• Approximately 40% increase in elderly and healthy subjects across short-term studies [3]
• 60% increase at six months and 73% at twelve months in the Alzheimer’s disease trial (563 participants) [25]
• 52-79% increase in growth hormone-deficient adults at doses of 10-50 mg per day [16]

These IGF-1 elevations are consistent and reproducible across study designs, making IGF-1 the most reliably modulated biomarker in MK-677 research.

MK-677 Brain Signaling: The Brake and Accelerator System (Preclinical Data)

The hypothalamus and pituitary use two competing signals to control GH output. GHRH (growth hormone-releasing hormone) acts as an accelerator, pushing the pituitary to release GH. Somatostatin acts as a brake, telling the pituitary to slow down. When MK-677 is given to rats over a prolonged period, the brain responds by increasing somatostatin production. More brake means the GH pulse signal becomes less effective over time [2]. In the same rat studies, the pituitary reduced the number of SSTR-2 receptors (somatostatin receptor subtype 2, the receptor that receives the brake signal). This appears to be a partial compensation, but it did not fully offset the increased somatostatin levels. The net result in these animal models was no measurable growth promotion despite confirmed GH pulse stimulation. Whether this counter-regulatory pattern occurs to the same degree in humans remains uncharacterized.

MK-677 Hormonal Selectivity

MK-677 has not significantly altered cortisol, prolactin, or thyroid hormone levels in most published trials. One 12-month study in elderly subjects documented a cortisol increase of 47 nmol/L, which reached statistical significance at P=0.020 [11]. This relatively selective hormonal profile is frequently cited as a potential advantage over exogenous GH administration, which can suppress endogenous GH axis activity and alter multiple hormonal systems simultaneously.

Proposed Downstream Effects

GH and IGF-1 elevation creates conditions studied for effects on nitrogen balance, lean tissue preservation, bone remodeling, and sleep architecture. GH secretion is predominantly nocturnal, with the largest pulse occurring shortly after sleep onset. Some research protocols have timed MK-677 administration at bedtime to align with this natural pattern [14]. Proposed downstream effects on tissue repair and inflammation remain largely theoretical in MK-677 research, without direct mechanistic confirmation in peer-reviewed human studies.

MK-677 Major Areas of Research

MK-677 ibutamoren research spans several distinct domains across human and preclinical study populations. Each area below provides a research-focused overview of findings, current status, and identified limitations.

MK-677 and Protein Catabolism Research

The earliest published human research on MK-677 examined its effects on diet-induced catabolism. Healthy men placed under caloric restriction experience negative nitrogen balance, meaning the body breaks down more protein than it synthesizes. This catabolic state models clinical conditions such as post-surgical recovery, illness-related muscle wasting, and starvation. In a 1998 study, 25 mg of oral MK-677 per day reversed diet-induced nitrogen loss. The MK-677 group shifted from a mean nitrogen balance of -2.67 grams per day to +0.31 grams per day. The placebo group remained at -1.48 grams per day (P less than 0.01) [10]. Peak GH on the first day of treatment reached 55.9 micrograms per liter. IGF-1 rose from 186 ng/mL to 264 ng/mL over the study period. This finding established MK-677’s anti-catabolic effect as a primary research interest, particularly for conditions involving protein wasting. Adverse effects documented in this trial included transient stomach discomfort, dizziness, diarrhea, and headache. One participant developed an elevated fasting glucose of 142 mg/dL. This was an early indicator of the metabolic effects that would become a recurring concern across subsequent trials. Key Research Highlights:

• Nitrogen balance reversed from negative to positive at 25 mg/day in healthy men under caloric restriction
• IGF-1 increased 36-42% from baseline
• Mild transient gastrointestinal effects documented; one case of elevated fasting glucose

MK-677 Body Composition Research in Elderly Adults

Age-related decline in GH secretion is called somatopause: the gradual reduction in growth hormone output that occurs naturally with aging, typically accelerating after age 30. Research into whether GH secretagogues can preserve lean body mass in older populations has motivated several MK-677 trials. A 12-month trial in elderly adults using 25 mg per day found that fat-free mass increased by 1.1 kg in the treated group, compared to a 0.5 kg decrease in the placebo group [11]. The 24-hour mean GH concentration rose 1.8-fold from baseline, with IGF-1 elevations maintained throughout the treatment period. A critical limitation of this study: despite measurable increases in fat-free mass, no improvement in muscle strength or physical function occurred. The dissociation between lean mass gain and functional outcomes constrains the practical significance of this finding for research focused on age-related physical decline. Short-term studies in elderly subjects (2-9 weeks, involving 187 participants across multiple trials) at doses of 10-50 mg per day reported no serious drug-related adverse events. These studies consistently showed sustained IGF-1 elevations and increased fat-free mass without measurable body fat reduction [3]. Key Research Highlights:

• 1.1 kg fat-free mass increase over 12 months versus 0.5 kg decrease in placebo
• No improvement in muscle strength or physical function despite lean mass gain
• Short-term studies generally well-tolerated across 187 elderly participants

MK-677 Bone Turnover Research

MK-677 stimulates both bone formation and bone resorption markers, producing an acceleration of bone turnover rather than a selective anabolic effect on bone. An 8-week trial in obese males at 25 mg per day measured specific bone marker changes:

• Carboxy-terminal propeptide of type I procollagen (a bone formation marker) increased 23% at two weeks (P less than 0.01)
• Osteocalcin (another bone formation marker) increased 15% at eight weeks (P less than 0.01)
• NTX (N-terminal cross-linking telopeptide, a bone resorption marker that signals how fast old bone is being broken down) increased 27-46% [15]

Separate studies in elderly subjects using 10-25 mg doses over 2-4 weeks showed similar elevations in osteocalcin and bone-specific alkaline phosphatase alongside IGF-1 rises [13]. The simultaneous elevation of formation and resorption markers indicates MK-677 accelerates overall bone turnover rather than producing net bone formation. Long-term effects on bone mineral density have not been adequately characterized in human studies. Key Research Highlights:

• Bone formation and resorption markers both elevated (turnover acceleration, not selective formation)
• Osteocalcin +15% at 8 weeks in obese males
• Long-term bone mineral density effects not established

MK-677 Research in Growth Hormone Deficiency

A dose-escalation study in adults with GH deficiency evaluated MK-677 at 10-50 mg per day across sequential dosing periods. IGF-1 increased 52-79%, and 24-hour mean GH concentration rose 79-82% at all doses studied. The study found greater GH response in subjects with less severe GH deficiency at baseline. Five of nine subjects at the 10 mg dose level experienced possibly drug-related clinical adverse events. This is a notable signal given 10 mg was the lowest dose tested in that cohort [16]. This population is one where GH replacement has established clinical precedent. Exogenous GH is FDA-approved for adult GH deficiency. Comparing MK-677 to approved GH treatment is a logical research question, but no clinical trial data confirms therapeutic equivalence or safety parity. Key Research Highlights:

• IGF-1 increased 52-79% across all doses
• 24-hour mean GH up 79-82%
• Adverse events in 5 of 9 subjects at the lowest dose studied (10 mg)

MK-677 Alzheimer’s Disease Research

The largest single MK-677 trial investigated whether GH/IGF-1 axis stimulation could slow the progression of Alzheimer’s disease. The IGF-1 hypothesis of Alzheimer’s disease proposed that declining IGF-1 with aging contributes to neurodegeneration, and that restoring IGF-1 might provide neuroprotection. The trial (NCT00074529) enrolled 563 participants and administered 25 mg per day of MK-677 for 12 months. IGF-1 rose 60% at six months and 73% at twelve months, confirming robust pharmacological activity [25]. Cognitive and functional outcomes were measured using four validated scales: ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, which measures memory and language function), ADCS-ADL (Alzheimer’s Disease Cooperative Study Activities of Daily Living, which tracks daily task performance), CDR-sob (Clinical Dementia Rating sum of boxes, a clinician-rated severity measure), and CIBIC+ (Clinician’s Interview-Based Impression of Change plus caregiver input, a global change rating). On every measured outcome, MK-677 produced no therapeutic benefit. Alzheimer’s disease progression was not slowed on any cognitive or functional scale despite sustained IGF-1 elevation throughout the trial. This null result in a well-powered trial effectively closed the IGF-1 hypothesis of Alzheimer’s neuroprotection as a viable research direction for MK-677, at least via the mechanism tested. Researchers studying related conditions may find useful context in the broader Alzheimer’s peptide therapeutics research literature. Key Research Highlights:

• Largest MK-677 trial: 563 participants, 12 months, 25 mg/day
• IGF-1 elevated 73% at 12 months (robust pharmacological effect confirmed)
• No slowing of Alzheimer’s progression on any cognitive or functional measure
• Critical null result in a well-powered, adequately dosed trial

MK-677 Body Composition Research in Obese Subjects

A two-month study in obese subjects found that MK-677 increased GH secretion, fat-free mass, and energy expenditure. Body fat reduction was not clearly demonstrated despite GH elevation [18]. This pattern, where GH-related anabolic measures improve without corresponding fat loss, has appeared across multiple MK-677 study populations. It complicates claims about MK-677’s utility as a fat loss research tool. Key Research Highlights:

• GH secretion and fat-free mass increased in obese subjects over two months
• Energy expenditure elevated
• Body fat reduction not clearly demonstrated

MK-677 Pharmacokinetics and Biological Distribution

Absorption and Oral Bioavailability

MK-677’s defining pharmacokinetic feature is oral bioavailability. Its non-peptide sulfonamide structure resists breakdown by digestive enzymes and survives gastric acid exposure, allowing sufficient absorption through the intestinal wall to achieve systemic concentrations. This distinguishes MK-677 from peptide-based growth hormone secretagogues such as GHRP-2 and ipamorelin, which are degraded in the gastrointestinal tract and require subcutaneous injection to reach the bloodstream. Clinical trial data confirm that orally administered MK-677 produces measurable pharmacological effects within hours of dosing. Peak GH concentrations of 55.9 micrograms per liter were recorded on the first day of a 25 mg oral dose protocol [10]. This rapid onset confirms that the oral route delivers therapeutically relevant systemic concentrations in humans.

Distribution and Tissue Targeting

Following absorption, MK-677 distributes systemically and crosses the blood-brain barrier to reach its primary receptor targets in the hypothalamus and anterior pituitary. GHS-R1a receptors in these brain regions mediate the GH-releasing response. The compound also binds peripheral GHS-R1a receptors present in other tissues, though the pituitary and hypothalamic actions drive the primary pharmacological effects observed in clinical research. The liver is a key secondary site of activity. GH released from the pituitary in response to MK-677 stimulates hepatic IGF-1 production. Consistently documented IGF-1 elevations of 40-79% across study populations confirm that this liver-mediated downstream effect is robust and reproducible [3, 10, 16].

Half-Life and Dosing Duration

MK-677 has a plasma half-life estimated at approximately 4-6 hours based on pharmacokinetic modeling from clinical studies. This relatively extended half-life, compared to peptide secretagogues which are cleared within minutes to an hour, supports once-daily oral dosing. All published human trials used single daily doses ranging from 5 to 50 mg, and IGF-1 elevations were sustained throughout 24-hour measurement periods, indicating sufficient systemic exposure from once-daily administration [14]. The prolonged half-life also means that bedtime dosing aligns the peak drug exposure window with the body’s natural nocturnal GH secretion pattern. Some research protocols have used this timing strategy to enhance physiological concordance with natural GH pulse rhythms.

Metabolism and Clearance

MK-677 undergoes hepatic metabolism. Specific metabolic pathways have not been fully characterized in published peer-reviewed literature, and detailed pharmacokinetic studies in special populations (renal impairment, hepatic impairment) remain limited. One registered clinical trial (NCT00395291) investigated MK-677 in end-stage renal disease patients on hemodialysis, measuring biomarkers including IGF-1 and inflammatory markers, but published outcomes from this trial were not available in reviewed literature [19]. Standard clearance occurs through hepatic biotransformation and renal excretion of metabolites. The absence of a complete published pharmacokinetic profile represents a genuine gap in the MK-677 research record, particularly for research applications involving subjects with impaired metabolic or renal function.

MK-677 Research Limitations and Evidence Gaps

Critical Null Results

The MK-677 research record includes several findings that meaningfully constrain enthusiasm about the compound’s research potential. Alzheimer’s disease (563 participants): Despite a 73% IGF-1 elevation sustained over 12 months, MK-677 produced no slowing of Alzheimer’s disease progression on any cognitive or functional scale. This is the largest and most rigorously designed trial in the MK-677 literature. Its null result on every pre-specified outcome is a primary limitation on the compound’s research trajectory [25]. No functional gains in elderly: A 12-month trial showed a 1.1 kg fat-free mass increase over placebo, but no corresponding improvement in muscle strength or physical function was observed. Lean mass gain without functional benefit is a well-recognized limitation in GH axis research. It reduces the practical significance of body composition findings in elderly populations [11]. No growth promotion in prolonged animal studies: Rat studies using extended MK-677 administration showed clear GH pulse stimulation but no measurable growth promotion. The proposed mechanism is the brain increasing its brake signal (somatostatin), which creates a counter-regulatory response that limits the growth effects of sustained GH stimulation [2]. Clinical trial halted for cardiac safety: At least one trial in growth hormone-deficient adults was stopped early. Four of 62 MK-677 subjects (6.5%) developed congestive heart failure (CHF), compared to 1 of 60 placebo subjects (1.7%). The FDA has flagged this as a significant safety risk in certain patient populations [7].

Human Clinical Data Gaps

• No large-scale long-term safety studies in healthy adults
• No confirmed peer-reviewed primary studies from 2022 through 2024 appear in available sources
• Most trials conducted in specific subpopulations (elderly, GH-deficient, obese) with limited generalizability
• Short study durations relative to the chronic conditions being studied
• No cancer incidence data from long-term trials, despite documented IGF-1 elevation raising theoretical oncological concerns

Mechanistic Uncertainties

• The brain’s counter-regulatory response (increased somatostatin) observed in rats has not been fully characterized in human subjects
• Whether this somatostatin response limits long-term GH-stimulating efficacy in humans is unknown
• Direct neuroprotective effects of MK-677 have not been confirmed in any reviewed human study
• Direct anti-inflammatory effects of MK-677 have not been confirmed in any reviewed human study

Methodological Weaknesses

The FDA has specifically noted that existing MK-677 studies feature small sample sizes, short durations, and lack of clinically meaningful therapeutic endpoints [7]. These criticisms apply broadly across the literature. The most meaningful exception is the Alzheimer’s trial (563 participants), which used validated clinical endpoints and produced null results.

Areas Needing Further Investigation

• Long-term safety profile in healthy adults (currently entirely uncharacterized beyond 12-month elderly data)
• Cancer incidence with sustained IGF-1 elevation (no adequate long-term data)
• Counter-regulatory mechanisms in humans and their implications for sustained research protocols
• Pharmacokinetics in renal impairment (a registered trial exists but published outcomes were not available in reviewed literature)
• Combination effects when used alongside selective androgen receptor modulators (community data suggests serum lipid disruption, but no peer-reviewed characterization exists)

MK-677 Regulatory and Research Status

FDA Status

MK-677 is not approved by the FDA for any human therapeutic indication. The agency classifies it as an investigational compound and has stated explicitly that it cannot be legally marketed as a dietary supplement or drug in the United States. FDA review of available clinical data identified significant safety risks, specifically congestive heart failure risk in certain populations. The agency also noted that existing studies lack the size, duration, and endpoint rigor needed to support approval consideration [7]. Sale as a “research chemical” persists in a regulatory gray area.

WADA Status

MK-677 ibutamoren is explicitly listed on the WADA 2024 Prohibited List under Category S2.2.4: Peptide Hormones, Growth Factors, Related Substances, and Mimetics [40, 41]. It is prohibited at all times, covering both in-competition and out-of-competition periods. The WADA prohibited listing was explicitly named in the 2024 update effective January 1, 2024, placing it alongside other growth hormone secretagogues including capromorelin and ipamorelin. USADA, UKAD, and the International Testing Agency have each confirmed this prohibition in their respective summaries of the 2024 Prohibited List changes [43, 44, 46]. Athletes subject to anti-doping rules in any sport governed by WADA-compliant codes must not use MK-677 regardless of administration route or claimed purpose. The classification logic recognizes MK-677 as a non-peptide mimetic of a peptide hormone, placing it under the “mimetics” subcategory that captures compounds with non-peptide structures but peptide receptor activity. WADA may also classify it under the S0 Non-Approved Substances category, which covers any pharmacological substance not approved by a regulatory authority for human therapeutic use when used for performance enhancement purposes.

International Perspective

No country has granted regulatory approval for MK-677 as a therapeutic agent. Most jurisdictions classify it as an unapproved investigational substance. Some maintain explicit controlled substance designations, while others regulate by general unapproved drug status. Researchers should consult jurisdiction-specific guidance before working with the compound.

Research Community Approach

Legitimate MK-677 research requires institutional review board oversight, appropriate biosafety protocols, and compliance with applicable controlled substance and research chemical regulations. The absence of clinical approval does not preclude institutional research under proper oversight. However, the halted clinical trial, FDA safety signals, and the Alzheimer’s null result have collectively reduced active pharmaceutical industry investment in MK-677’s clinical development pathway. Research on MK-677 is often discussed alongside related compounds including GHRP-2, GHRP-6, ipamorelin, and sermorelin, which target similar GH axis pathways through different mechanisms. Researchers interested in growth hormone axis modulation may also want to review data from BPC-157, whose tissue repair mechanisms involve growth factor signaling pathways. The BPC-157 and organ protection research literature provides relevant context for growth factor pathway research. Those sourcing reference-grade compounds for institutional research should note that purity verification is essential with MK-677. Community reports have flagged heavy metal contamination concerns in some research chemical market products.

MK-677 Key Research Findings

Nitrogen Balance Reversal (1998, Healthy Men)

Research Focus: Whether oral MK-677 could reverse diet-induced protein catabolism in healthy men Key Results: Nitrogen balance shifted from -2.67 g/day to +0.31 g/day in the MK-677 group versus -1.48 g/day in placebo (P less than 0.01). IGF-1 rose from 186 ng/mL to 264 ng/mL (36-42% increase). Peak GH reached 55.9 micrograms per liter on day one. Significance: Established MK-677’s anti-catabolic effect as a primary research application. Confirmed oral bioavailability and GH/IGF-1 axis engagement. Limitations: Short duration (approximately one week); healthy young male population limits generalizability; one case of elevated fasting glucose (142 mg/dL) signaled the metabolic risk that would recur in subsequent research [10]

Body Composition in Elderly Adults (12 Months)

Research Focus: Fat-free mass and GH secretion in elderly adults over 12 months at 25 mg per day Key Results: Fat-free mass increased +1.1 kg (MK-677) versus -0.5 kg (placebo). 24-hour mean GH rose 1.8-fold from baseline. IGF-1 sustained throughout. Cortisol raised 47 nmol/L (P=0.020). Significance: Longest human trial published. Confirms sustained IGF-1 elevation is achievable. Provides the best available long-term tolerability data in elderly subjects. Limitations: No improvement in muscle strength or physical function; cortisol elevation statistically significant; results specific to elderly population [11]

Alzheimer’s Disease Trial (NCT00074529, 563 Participants)

Research Focus: Whether sustained IGF-1 elevation via 25 mg daily MK-677 over 12 months could slow Alzheimer’s disease progression Key Results: IGF-1 rose 60% at six months, 73% at twelve months. Null results on ADAS-Cog, ADCS-ADL, CDR-sob, and CIBIC+ scales. Significance: Largest, most rigorously designed MK-677 trial. Definitively tests and refutes the IGF-1 hypothesis of Alzheimer’s neuroprotection via this mechanism. Robust pharmacological engagement did not translate to clinical benefit. Limitations: Restricted to Alzheimer’s population; does not address other research applications; IGF-1 elevation is not a surrogate endpoint for disease modification [25]

Congestive Heart Failure Signal (Growth Hormone-Deficient Adults Trial)

Research Focus: MK-677 in growth hormone-deficient adults (trial halted early) Key Results: 4 of 62 MK-677 subjects (6.5%) developed congestive heart failure versus 1 of 60 placebo subjects (1.7%). Trial stopped early. Significance: Most serious safety finding in the MK-677 research record. Directly contributed to FDA’s safety risk designation. Substantially limits further development in cardiac-risk populations. Limitations: Specific to growth hormone-deficient population with potentially different cardiac risk profiles than healthy adults; absolute numbers are small [7]

Bone Turnover Acceleration (Obese Males, 8 Weeks)

Research Focus: Bone turnover markers in obese males at 25 mg per day over 8 weeks Key Results: Carboxy-terminal propeptide of type I procollagen +23% at two weeks. Osteocalcin +15% at eight weeks. NTX (bone resorption marker) +27-46%. Significance: Confirms MK-677 activates bone remodeling. Both formation and resorption markers elevated, indicating turnover acceleration rather than selective anabolic bone effect. Limitations: Short duration; effect on net bone mineral density over time not established; obese male population [15]

Preclinical Counter-Regulatory Findings (Rat Models)

Research Focus: Mechanistic effects of prolonged MK-677 in rat models Key Results: Hypothalamic somatostatin (the brain’s GH brake hormone) increased at the mRNA and protein level. Pituitary SSTR-2 (somatostatin receptor subtype 2, which receives the brake signal) decreased at the mRNA and protein level. No growth promotion occurred despite confirmed GH stimulation. GH response desensitized over 6 weeks at 4 mg/kg. Significance: Identifies a counter-regulatory mechanism that may limit long-term GH-stimulating efficacy. Provides preclinical rationale for why sustained growth effects may not match initial GH pulse data. Limitations: Rat models; translational applicability to human physiology unconfirmed [2]

Frequently Asked Questions

What is MK-677 ibutamoren?

MK-677, also called ibutamoren, is a synthetic small molecule studied for its ability to stimulate growth hormone release. It works by activating the same receptor that the hunger hormone ghrelin activates, triggering the pituitary gland to release growth hormone. Unlike growth hormone injections, MK-677 is taken by mouth, which made it an object of significant research interest starting in the 1990s. It is classified as a research compound and has not been approved for human therapeutic use by any regulatory authority.

Is MK-677 a peptide?

No. MK-677 is not a peptide. It is a non-peptide small molecule that mimics the action of ghrelin, which is itself a peptide hormone. True peptide growth hormone secretagogues such as GHRP-2 and GHRP-6 require injection because their peptide bonds are broken down by digestive enzymes. MK-677’s non-peptide chemical structure survives oral administration, which is the primary structural reason it can be taken by mouth.

What have clinical trials found about MK-677?

Human trials have confirmed that MK-677 reliably elevates growth hormone and IGF-1 across multiple study populations. Specific findings include reversal of diet-induced nitrogen loss in healthy men, modest increases in fat-free mass in elderly adults, and acceleration of bone turnover markers. A major 563-person Alzheimer’s disease trial found no benefit on cognitive or functional outcomes despite robust IGF-1 elevation. At least one trial was halted early due to a higher rate of congestive heart failure in the MK-677 group compared to placebo.

What are the known safety concerns with MK-677 research?

Documented safety concerns from clinical research include insulin resistance and elevated fasting glucose across multiple study populations, congestive heart failure in growth hormone-deficient adult trial participants (6.5% versus 1.7% placebo), water retention and edema, and joint and muscle pain. Long-term safety in healthy adults has not been established, and sustained IGF-1 elevation raises theoretical concerns about cancer risk that have not been characterized in long-term trials.

Is MK-677 prohibited in sport?

Yes. MK-677 ibutamoren is explicitly listed on the WADA 2024 Prohibited List under Category S2.2.4 covering growth hormone secretagogues and related mimetics. It is prohibited at all times, meaning both in-competition and out-of-competition use is banned for athletes subject to anti-doping rules. USADA, UKAD, and other national anti-doping organizations have confirmed this prohibition in their 2024 Prohibited List summaries.

References

1. Operative Supplement Solutions (OPSS). MK-677 ibutamoren performance-enhancing substance summary. opss.org
2. Peng, X.D., et al. (2018). Prolonged administration of MK-677 in rats affects hypothalamic and pituitary somatostatin and GH signaling. PMC. PMC6240568
3. Copinschi, G., et al. (1998). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Journal of Clinical Endocrinology and Metabolism, 83(2), 320-324. JCEM
4. Murphy, M.G., et al. (1998). MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology and Metabolism. PubMed
5. Nass, R., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Journal of Clinical Endocrinology and Metabolism. PubMed
6. Nass, R., et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. PMC. PMC2757071
7. U.S. Food and Drug Administration. FDA safety communication regarding MK-677 and congestive heart failure risk. FDA
8. Nass, R., et al. (1999). Bone turnover and skeletal effects of MK-677, a growth hormone secretagogue, in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. PubMed
9. Chapman, I.M., et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. PubMed
10. Murphy, M.G., et al. (1998). MK-677 reversal of diet-induced nitrogen loss in healthy men. Journal of Clinical Endocrinology and Metabolism. PubMed
11. Nass, R., et al. (2008). Twelve-month oral ghrelin mimetic trial in elderly adults: body composition, GH, and IGF-1 outcomes. Journal of Clinical Endocrinology and Metabolism. PubMed
12. Svensson, J., et al. (1998). Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677. Journal of Clinical Endocrinology and Metabolism. PubMed
13. Nass, R., et al. (1999). Bone turnover markers in elderly subjects treated with MK-677. Journal of Clinical Endocrinology and Metabolism. PubMed
14. Chapman, I.M., et al. (1996). Bedtime dosing and 24-hour GH profiles with MK-677 in healthy elderly and young men. Journal of Clinical Endocrinology and Metabolism. PubMed
15. Svensson, J., et al. (1998). Bone turnover acceleration in obese males: MK-677 8-week trial findings. Journal of Clinical Endocrinology and Metabolism. PubMed
16. Bowers, C.Y., et al. (1997). MK-677, an orally active growth hormone secretagogue, in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism. PubMed
17. PMC. MK-677 ibutamoren short-term tolerability and safety review. PMC5632578
18. Unbound Medicine. Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677: GH secretion, fat-free mass, and energy expenditure. Unbound Medicine
19. ClinicalTrials.gov. NCT00395291: MK-677 effects on IGF-1 and biomarkers in end-stage renal disease patients on hemodialysis. ClinicalTrials.gov
20. ClinicalTrials.gov. NCT01343641: MK-677 effects on lean body mass. ClinicalTrials.gov
21. ClinicalTrials.gov. NCT00074529: MK-677 for treating Alzheimer’s disease (563 participants, completed). ClinicalTrials.gov
22. WADA. 2024 Prohibited List explanatory notes. WADA
23. WADA. 2024 Prohibited List (official). WADA
24. USADA. Key changes to the 2024 Prohibited List. USADA
25. UKAD. 2024 Prohibited List summary of changes. UKAD
26. ITA. What you need to know about the WADA 2024 Prohibited List. ITA Sport